Roche closed 2025 with 7% group sales growth at constant exchange rates, powered by a 9% rise in Pharmaceuticals and a 2% uptick in Diagnostics, alongside double‑digit core profit and EPS growth. The year delivered multiple value catalysts: US and EU approvals for subcutaneous Lunsumio in follicular lymphoma, EU approval of Gazyva/Gazyvaro in lupus nephritis, positive phase III readouts for fenebrutinib in both relapsing and primary progressive multiple sclerosis and for giredestrant in early ER‑positive breast cancer, and a phase II obesity signal for dual GLP‑1/GIP agonist CT‑388 with placebo‑adjusted weight loss of 22.5% at 48 weeks. Roche advanced 10 molecules into phase III and guided to mid single‑digit sales and high single‑digit core EPS growth for 2026, while completing the tender offer step toward acquiring 89bio.
The immediate strategic question is whether Roche is successfully converting a post‑COVID reset into durable, innovation‑led growth that can withstand intensifying price pressure and portfolio self‑cannibalization. The mix shift is clear: five growth brands—Ocrevus, Hemlibra, Vabysmo, Xolair, and Phesgo—added CHF 3.2 billion, more than offsetting CHF 0.7 billion in erosion from legacy biologics. Yet the most consequential pipeline wins now sit squarely in franchises Roche already dominates. Fenebrutinib, if approved as the first BTK inhibitor to show benefit in both RMS and PPMS, could protect and expand Roche’s MS leadership but will inevitably compete with Ocrevus. The commercial imperative is to manage an orderly migration: segment patients by disease biology and treatment setting, price and contract to retain share across the class, and lean into outcomes and adherence advantages of an oral option without sacrificing the anti‑CD20 cash engine.
Subcutaneous oncology is becoming a defining capability. Lunsumio’s one‑minute administration, together with the continued conversion from Perjeta to Phesgo, frees infusion chair time, supports outpatient delivery, and can lower total cost of care—an increasingly salient lever with site‑neutral payment policies and capacity constraints. For payers and providers, the value proposition is operational as much as clinical; for competitors, it raises the bar on convenience, especially as combination regimens move earlier in lymphoma. Medical Affairs teams will need to seed real‑world data on adherence, administration setting, and resource utilization to lock in formulary advantage.
In breast cancer, giredestrant’s superiority in invasive disease‑free survival in the adjuvant setting represents the first meaningful endocrine advance in two decades, but the hurdle will be economic. Replacing low‑cost aromatase inhibitors in early disease will demand long‑horizon outcomes, recurrence‑related cost offsets, and precision positioning to avoid overtreatment. Expect payer demands for biomarker‑enriched evidence and extended follow‑up; the burden shifts to RWE, survivorship endpoints, and patient‑reported outcomes to sustain premium pricing.
Roche’s push into obesity with CT‑388 signals alignment with the broader cardiometabolic land grab, yet commercialization will hinge on manufacturing scale, cardiovascular outcomes, and primary care integration. The Diagnostics portfolio is being tuned accordingly: automated mass spectrometry for therapeutic drug monitoring, women’s health and infectious disease assays, and point‑of‑care tests that shorten time to decision. That matters as China’s pricing reforms weigh on lab revenues; moving to high‑medical‑value, workflow‑friendly platforms is a defensible strategy in tender‑driven markets.
The through line is portfolio resilience built on modality diversification, administration innovation, and evidence depth. The next test arrives quickly: can Roche grow MS share while migrating patients to fenebrutinib, convert adjuvant breast cancer based on early wins without eroding payer trust, and scale an obesity entrant amid capacity and outcomes scrutiny? If execution matches the pipeline, the company may turn 2025’s momentum into a multi‑year compounding cycle. The counterfactual is equally clear: in a world of tightening price controls and crowded cardiometabolic markets, who captures the operational delta—Roche with integrated Pharma‑Dx and SC delivery, or fast followers with sharper contracting and outcomes data?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
